The stock of AngioDynamics, Inc. (NASDAQ:ANGO) is a huge mover today! About 1.42M shares traded hands or 245.27% up from the average. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 52.37% since April 13, 2016 and is uptrending. It has outperformed by 48.44% the S&P500.
The move comes after 7 months negative chart setup for the $609.52M company. It was reported on Nov, 15 by Barchart.com. We have $15.23 PT which if reached, will make NASDAQ:ANGO worth $42.67 million less.
AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage
Out of 6 analysts covering AngioDynamics (NASDAQ:ANGO), 2 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 33% are positive. AngioDynamics has been the topic of 8 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The stock has “Sell” rating given by Zacks on Monday, August 31. The rating was downgraded by Raymond James to “Mkt Perform” on Tuesday, November 10. Canaccord Genuity downgraded the shares of ANGO in a report on Tuesday, April 5 to “Hold” rating. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Buy” rating by Cantor Fitzgerald on Friday, November 4. Sidoti initiated AngioDynamics, Inc. (NASDAQ:ANGO) on Wednesday, September 23 with “Neutral” rating. The rating was maintained by Canaccord Genuity with “Buy” on Friday, January 8. The stock has “Overweight” rating given by KeyBanc Capital Markets on Friday, July 24. As per Friday, April 8, the company rating was reinitiated by Piper Jaffray.
According to Zacks Investment Research, “AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company’s diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products.”
Insitutional Activity: The institutional sentiment increased to 1.87 in 2016 Q2. Its up 0.50, from 1.37 in 2016Q1. The ratio is positive, as 11 funds sold all AngioDynamics, Inc. shares owned while 20 reduced positions. 10 funds bought stakes while 48 increased positions. They now own 24.22 million shares or 1.02% less from 24.47 million shares in 2016Q1.
Dimensional Fund Advsr Lp accumulated 2.97M shares or 0.02% of the stock. Tfs Ltd Liability Co last reported 42,097 shares in the company. American Intl Grp accumulated 19,991 shares or 0% of the stock. Tower Rech Cap Limited Company (Trc) reported 482 shares or 0% of all its holdings. Sentinel Asset Incorporated has 0.33% invested in the company for 965,616 shares. Rhumbline Advisers owns 38,500 shares or 0% of their US portfolio. Teton Advsrs last reported 60,866 shares in the company. Moreover, Secor Capital Advsrs L P has 0.07% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 36,017 shares. The New York-based Ny State Common Retirement Fund has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Kbc Group Nv reported 28,568 shares or 0.01% of all its holdings. Geode Management Limited Liability, a Massachusetts-based fund reported 202,875 shares. Pnc Financial Service Group Inc accumulated 12,717 shares or 0% of the stock. Swiss Bancorp accumulated 48,900 shares or 0% of the stock. Panagora Asset accumulated 0% or 31,077 shares. Tiaa Cref Mngmt Ltd holds 0% or 123,333 shares in its portfolio.
Insider Transactions: Since August 5, 2016, the stock had 0 buys, and 2 selling transactions for $65.66 million net activity. Shares for $32.76 million were sold by Avista Capital Partners GP – LLC on Friday, August 5. 2.25M shares were sold by Burgstahler David F, worth $32.90M on Friday, August 5.
More important recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: Globenewswire.com which released: “AngioDynamics Announces Pricing of Secondary Offering by Selling Stockholders” on November 15, 2016, also Streetinsider.com published article titled: “AngioDynamics (ANGO) Prices 2.5M Share Secondary Offering for Proceeds of ~$40M”, Prnewswire.com published: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating …” on September 19, 2016. More interesting news about AngioDynamics, Inc. (NASDAQ:ANGO) was released by: Nasdaq.com and their article: “Earnings Reaction History: AngioDynamics Inc., 75.0% Follow-Through Indicator …” with publication date: October 05, 2016.
ANGO Company Profile
AngioDynamics, Inc., incorporated on July 30, 1992, designs, makes and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.